

Reinfection after successful eradication of *Helicobacter pylori* in three different populations in Alaska

M. G. BRUCE^{1*}, D. L. BRUDEN¹, J. M. MORRIS¹, A. L. REASONOVER¹,
F. SACCO², D. HURLBURT¹, T. W. HENNESSY¹, J. GOVE³, A. PARKINSON¹,
G. SAHAGUN⁴, P. DAVIS², J. KLEJKA⁵ AND B. J. McMAHON^{1,3}

¹ Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases, Centers for Disease Control and Prevention (CDC), Anchorage, Alaska, USA

² The Alaska Native Medical Center, Anchorage, Alaska, USA

³ Liver Disease and Hepatitis Program, Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA

⁴ Internal Medicine Associate Inc., Anchorage, Alaska, USA

⁵ Yukon Kuskokwim Health Corporation, Bethel, Alaska, USA

Received 24 February 2014; Final revision 13 June 2014; Accepted 23 June 2014;
first published online 28 July 2014

SUMMARY

We performed a study to determine rates of reinfection in three groups followed for 2 years after successful treatment: American Indian/Alaska Native (AI/AN) persons living in urban (group 1) and rural (group 2) communities, and urban Alaska non-Native persons (group 3). We enrolled adults diagnosed with *H. pylori* infection based on a positive urea breath test (¹³C-UBT). After successful treatment was documented at 2 months, we tested each patient by ¹³C-UBT at 4, 6, 12 and 24 months. At each visit, participants were asked about medication use, illnesses and risk factors for reinfection. We followed 229 persons for 2 years or until they became reinfected. *H. pylori* reinfection occurred in 36 persons; cumulative reinfection rates were 14·5%, 22·1%, and 12·0% for groups 1, 2, and 3, respectively. Study participants who became reinfected were more likely to have peptic ulcer disease ($P=0\cdot02$), low education level ($P=0\cdot04$), or have a higher proportion of household members infected with *H. pylori* compared to participants who did not become reinfected ($P=0\cdot03$). Among all three groups, reinfection occurred at rates higher than those reported for other US populations (<5% at 2 years); rural AI/AN individuals appear to be at highest risk for reinfection.

Key words: Alaska Natives, *Helicobacter pylori*, indigenous, reinfection.

INTRODUCTION

Helicobacter pylori is a common pathogen of the gastric mucosa and a major cause of peptic ulcer

disease and is associated with chronic gastritis, mucosa-associated lymphoid tissue lymphoma, and adenocarcinoma of the stomach [1]. Infection with this bacterium has been found in persons residing in developed countries (6–40% seroprevalence) and those in developing nations (50–90% seroprevalence) [2–4]. A limited number of antimicrobial agents have activity against *H. pylori* and treatment requires two or three agents usually administered with a

* Author for correspondence: M. G. Bruce, MD, MPH, Arctic Investigations Program, Division of Preparedness and Emerging Infections, National Center for Emerging Zoonotic and Infectious Diseases, CDC, Anchorage, AK 99508, USA.
(Email: zwa8@cdc.gov)

proton pump inhibitor (PPI) for a 7- to 14-day course [5].

The proportion of persons who become reinfected after successful eradication of the organism ranges widely. In developing countries, annual reinfection rates vary widely from <10% [6, 7] to >50% [8, 9] and are lower in developed countries, usually <10% [10–13]. However, few studies have looked at risk factors for reinfection [14, 15].

Alaska Native (AN) persons have a 75–80% seroprevalence for antibodies to *H. pylori* [16, 17]. Seroprevalence of antibody to *H. pylori* was 32% in children aged 0–4 years and increased to 78% in 10- to 14-year-olds, remaining at that level within all older age groups [16]. We prospectively followed American Indian/Alaska Native (AI/AN) and Alaska non-Native (NN) patients diagnosed with *H. pylori* to determine the reinfection rates over a 2-year period and risk factors for reinfection after successful eradication of *H. pylori*. Objectives of our study were to determine: (1) post-eradication reinfection rates in the following three groups: AI/AN living in the largest metropolitan city (Anchorage, group 1), AI/AN living in rural, isolated communities (group 2), and NN living in Anchorage (group 3); (2) risk factors associated with reinfection; and (3) the prevalence of *H. pylori* infection in household members of the study participants.

METHODS

From 1 September 1998 to 30 March 2005, patients scheduled for oesophagogastroduodenoscopy (OGD) were recruited at the Alaska Native Medical Center, two private practice settings in Anchorage, one large hospital and one Gastroenterology clinic, and at the following three rural hospitals: the Yukon Kuskokwim Regional hospital in Bethel, the Kakanak hospital in Dillingham (Bristol Bay) and the Norton Sound hospital in Nome (Norton Sound). Study participants had to be aged ≥ 18 years and a resident of the region where their endoscopy was performed. The population of Anchorage, the largest urban metropolitan area in Alaska, is about 300 000 persons (<http://quickfacts.census.gov/qfd/states/02/0203000.html>). In contrast, the combined population of the three rural regions participating in the study (the Yukon Kuskokwim Delta, population 25 000; Bristol Bay, population 6 000; and Norton Sound, population 9 700) is 40 700. Patients were excluded from the study if they had a history of gastric cancer,

gastric resection, were pregnant or had undergone cancer chemotherapy or immunosuppressive therapy within the previous year.

Patients were enrolled at the initial visit if they were found to have a positive ^{13}C -urea breath test (^{13}C -UBT, Meretek Diagnostics Inc., USA) for *H. pylori*; however, only those enrollees who were treated and documented as being cured (*H. pylori*-negative) by ^{13}C -UBT were entered into the 2-year long-term reinfection study. Information regarding results for *H. pylori* from histology, culture, and CLOtest[®] on biopsy tissue (Ballard Medical Products, USA) was collected on each participant. Upon enrolment, a medical record review was conducted to determine if there was a history of: peptic ulcer disease, gastric surgery, gastritis, previous treatment for *H. pylori*, or evidence of medication prescribed for acid suppression treatment as previously reported [18]. Patients who tested positive for *H. pylori* were treated with an antibiotic regimen selected by the patient's provider, as previously reported [19]. Compliance with taking medicines was monitored with twice-weekly phone calls from a study nurse and treatment completion date was recorded. Patients who were taking a histamine 2 (H2) blocker or PPI were asked to stop taking these medications for at least 3 days prior to all follow-up ^{13}C -UBT testing. Patients who tested ^{13}C -urea breath test-positive for *H. pylori* at 8 weeks were offered a second treatment regimen at the provider's discretion. Patients who tested ^{13}C -UBT-negative for *H. pylori* 8 weeks after the treatment start date continued in the long-term follow-up portion of the study and were subsequently tested for *H. pylori* recurrence by ^{13}C -UBT at 4, 6, 12, and 24 months after treatment. At each follow-up visit, patients were interviewed to determine recent history of antimicrobial use, gastrointestinal symptoms, and risk factors for reinfection. At the end of the follow-up period, or at the time a patient became reinfected, current household members of the study participant were invited to be tested for *H. pylori* by ^{13}C -UBT. Follow-up OGD for those who became reinfected was not part of the study protocol. Patients who became reinfected and household members who were found to be positive for infection with *H. pylori* were referred back to their providers after study completion.

The following risk factor variables were collected from each participant and entered into the univariate analysis: age, sex, household crowding, presence of a child aged <5 years in the household, employment, education level, alcohol consumption, tobacco use,

private well water, consuming of water from lake, spring or river, travel within Alaska, pet ownership, diagnosis of an ulcer, previous *H. pylori* treatment, presence of moderate to severe gastritis and pre-mastication of food. For risk factors, we used the result collected at the time of enrolment with the exception of private well water, and consumption of lake, spring or river water. For these, if participant answered 'yes' at any point after the 2-month follow-up they were considered as having that risk factor. For risk factors where we used the result in the enrolment interview, we conducted sensitivity analyses using the information collected in the visit just prior to study endpoint. Results were unchanged and not reported. The following risk factor variables were entered into the multivariate model: household crowding, employment status, education level, tobacco use, consumption of lake spring, or river water, travelling within Alaska, pet ownership, diagnosis of an ulcer, previous *H. pylori* treatment, and moderate to severe gastritis.

The Institutional Review Boards of the Centers for Disease Control and Prevention, Indian Health Service, Alaska Area Tribal Health Consortium, and the Western IRB approved the study. In addition, the study was approved by the Southcentral Foundation, The Norton Sound Health Corporation, Yukon Kuskokwim Health Corporation and the Bristol Bay Area Health Corporation. Written informed consent was obtained from all participants.

Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Laboratory testing

Gastric biopsies were processed and inoculated to solid media as described previously [18]. One biopsy, usually from the antrum, was taken for the CLOtest[®] (an agar medium containing urea and a pH sensitive indicator) for the detection of urease. Gastric biopsy tissue obtained at the time of OGD were stained with Diff-Quik[®] (Mercedes Medical, USA) stain, for identification of *H. pylori* and with haematoxylin and eosin stain for histological evaluation.

Statistical methods

Reinfection rates were calculated using a Kaplan–Meier estimate. Statistical tests of risks factors were conducted using a Cox proportional hazards model. Participants were censored at the visit of reinfection or their final visit if they were not reinfected. Univariate tests were run, and those risk factors with a univariate *P* value <0.25 were considered in multivariate models as well as age and sex which have previously been associated with *H. pylori* reinfection. Because of lower power associated with the sample size of patients with *H. pylori* reinfections, the multivariate model was built using purposeful forward selection [20]. Variables were considered confounders and remained in the model if their exclusion changed the value of the coefficient(s) of interest by >15% [20]. Two additional risk factors were examined separately because they were not available and/or relevant for all participants. We tested household members of persons reinfected and those not reinfected on their last study visit for their *H. pylori* infection status using the ¹³C-UBT test. All household members were invited to participate. Fifty-four percent (123/229) of the long-term participants had household members who were tested for *H. pylori*; a total of 324 household members were tested. In a retrospective questionnaire conducted after the end of the study, we ascertained whether participants in the rural arm lived in households with in-home running water; all participants living in the urban centre of Anchorage, Alaska had access to running water and were eliminated from this sub-analysis. Presence of running water in the household, and household members who were *H. pylori* positive, were tested on a univariate basis using methods described previously. Statistical analysis was performed by using StatXact 9 (Cytel Software Corp., USA) and SAS software v. 9.3 (SAS Institute Inc., USA). *P* values are two-sided and confidence limits and *P* values are exact when appropriate.

RESULTS

During the study period, 582 patients were enrolled in the study and 571 had an OGD completed (Fig. 1). A total of 362 persons tested positive for *H. pylori* by ¹³C-UBT and were eligible for antimicrobial treatment. Treatment recommendations and choice of antimicrobial regimen were at the discretion of clinical providers; 333 (92%) *H. pylori*-positive persons were treated with an antimicrobial




Fig. 1. Flow diagram of participation in the Alaska reinfection study in three different populations. AN, Alaska Native; NN, Alaska non-Native.

regimen; 236 persons were eligible for long-term follow-up, 200 after their first treatment for *H. pylori*, 30 after their second treatment, and an additional six persons after their third treatment (Fig. 1), and 229 (97%) participated in long-term follow-up for *H. pylori* reinfection. Seven persons moved from the study area or were lost to follow-up after completion of the 2-month visit. There were 98 participants in group 1 (the urban AI/AN arm), 69 persons in group 2 (the rural AI/AN arm) and 62 persons in group 3 (the urban NN Alaskan arm) of the study. Characteristics of study participants according to study arm are shown in Table 1. The median age of all participants was 51 years and 55% of participants were female. Among participants who tested positive

for *H. pylori* by ¹³C-UBT, 85% (272/322), 90% (306/341), and 84% (242/289), were positive by CLOtest[®], culture and histology, respectively.

Participants in long-term follow-up

The analyses that follow were restricted to the 229 patients who had ≥1 visit after the 2-month test of cure. Of those in long-term follow-up, 216 (91%) completed the 2-year follow-up or were reinfected. Three patients were lost to follow-up after the 4-month follow-up visit, three patients after the 6-month follow-up visit, and seven patients after the 1-year visit. Demographic characteristics, OGD evaluation, self-reported symptoms and medical history at the time

Table 1. Characteristics of patients at enrolment who entered into long-term follow-up ($n=229$) for *H. pylori* reinfection

Characteristic	% with characteristic (N)		
	Group 1 Urban AN ($n=98$)	Group 2 Rural AN ($n=69$)	Group 3 Urban NN ($n=62$)
Female	57% (56)	52% (36)	53% (33)
Age, years (median)	47	51	56
Currently employed	56% (55)	58% (40)	61% (38)
In house >1 persons/per room	30% (29)	52% (36)	18% (11)
Private well water	24% (23)	32% (22)	16% (10)
Smoke	52% (51)	41% (28)	26% (16)
Drink alcohol	48% (47)	26% (18)	40% (25)
Endoscopy evaluation			
Gastritis grade			
Severe	6% (6)	3% (2)	14% (5)
Moderate	35% (34)	34% (23)	44% (16)
Mild	44% (43)	45% (30)	42% (15)
None	15% (15)	18% (12)	0% (0)
Ulcer	11% (11) 3 with duodenal ulcer	6% (4)	5% (2/37)
Duodenitis	20% (20/97)	15% (10/67)	24% (8/34)
Oesophagitis	24% (24)	18% (12/68)	32% (11/34)
Self-reported symptoms			
Stomach pain	86% (84)	74% (51)	76% (47)
Vomiting	35% (34)	32% (22)	21% (13)
Nausea	69% (68)	54% (37)	50% (31)
Heartburn	73% (72)	67% (46)	58% (36)
Medical history (medical chart review)			
Peptic ulcer disease (ever)	14% (14)	19% (13)	10% (6/61)
Gastric surgery (ever)	1% (1)	1% (1/68)	2% (1)
Gastritis (past 5 years)	35% (34/97)	54% (36/67)	15% (9/60)
Chronic stomach problems (past 5 years)	79% (77)	77% (51/66)	55% (34)
Previous upper endoscopy (ever)	19% (18/97)	32% (21/66)	20% (12/59)
Treated for <i>H. pylori</i> (past 10 years)	12% (12)	25% (15/61)	13% (8/61)

AN, Alaska Native; NN, Alaska non-Native.
Values given are % (n).

of enrolment for the 229 participants involved in long-term follow-up are shown in Table 1. Most participants at enrollment reported stomach pain (79%), nausea (59%) or heartburn (67%) and 30% complained of vomiting prior to treatment.

Long-term follow-up and reinfection rate

During the 2-year follow-up period, a total of 36 persons were reinfected with *H. pylori*: 14 at 4 months, seven at 6 months, five at 12 months, 10 at 24 months for an overall reinfection rate of 16.1% (Table 2). Cumulative reinfection rates at 2 years were highest (22%) among rural AN persons (group 2) compared

to urban AN persons (group 1) and urban NN persons (group 3) who had reinfection rates of 14.5% and 12%, respectively. In order to eliminate any cases that could have occurred due to recrudescence, we removed the 14 patients who had positive ^{13}C -UBTs at 4 months after treatment and determined that the cumulative reinfection rate for all arms would be 3.3% (95% CI 1.6–6.8) at 6 months, 5.7% (95% CI 3.3–9.8) at 1 year, and 10.7% (95% CI 7.1–15.7) at 2 years. In a *post-hoc* analysis of data within group 2, the reinfection rate in the Yukon Kuskokwim Delta region at 2 years was 29.9% (95% CI 18.2–46.4) which trended higher than in the Norton Sound and Bristol Bay regions combined (10.7%, 95% CI 3.6–29.6, $P=0.06$)

Table 2. Two-year cumulative reinfection rate among three groups, Alaska

	Group 1 Urban AN (n=98)		Group 2 Rural AN (n=69)		Group 3 Urban NN (n=62)		Overall	
	% Reinfected	Cumulative reinfection rate	% Reinfected	Cumulative reinfection rate	% Reinfected	Cumulative reinfection rate	% Reinfected	Cumulative reinfection rate
4 months	5	5.1%	7	10.1%	2	3.2%	14	6.1%
6 months	2	7.2%	2	13.0%	3	8.2%	7	9.2%
12 months	3	10.3%	2	16.0%	0	8.2%	5	11.5%
24 months	4	14.5%	4	22.0%	2	12.0%	10	16.1%

AN, Alaska Native; NN, Alaska non-Native.

and was higher than in group 1 ($P=0.03$). We detected no difference in the prevalence of symptoms (heartburn, nausea, stomach pain, vomiting) between reinfected patients and non-reinfected patients on their last visit. Of the 36 participants with reinfections, 15 (42%) reported no change in their symptoms at the final reinfection visit, six (17%) reported a worsening of symptoms, 13 (36%) reported improvement of their symptoms, and two (5%) persons reported new symptoms.

Risk factors for reinfection

For all three arms combined, we examined a variety of risk factors for reinfection with *H. pylori*. On univariate analysis, we found that risk of *H. pylori* reinfection was associated with living in a crowded house [defined as ≥ 1 person per room, risk ratio (RR) 2.3 95% CI 1.2–4.4], not having graduated from high school (RR 0.4 95% CI 0.2–0.8), an ulcer diagnosis (either at enrolment or having a history of ulcers, RR 2.4, 95% CI 1.2–4.8) and consumption of lake, spring or river water (RR 2.0, 95% CI 1.0–3.9, Table 3). On multivariate analysis, for all three arms combined, we found that risk of reinfection was associated with diagnosis of ulcer (RR 2.3, 95% CI 1.2–4.5) and graduating from high school (RR 0.4, 95% CI 0.2–0.9). The multivariate results were similar for ulcer and high school in a model that additionally included age and sex. Trends for reinfection rates showed that among those who had not graduated from high school, reinfection rates were higher (compared to persons who did graduate) in each of the three study arms (group 1:33% vs. 12%; group 2:31% vs. 17%; group 3: 27% vs. 8%); however, these trends were not statistically significantly different. Living in a crowded house was also statistically significant ($P=RR 2.0$, 95% CI 1.0–4.0) in a two-variable model with ulcer diagnosis, but the P value dropped to 0.11 in a three-variable model which included ulcer diagnosis and graduating high school.

Additional risk factors

Household member prevalence and reinfection in study participants

Three hundred and twenty-four (70%) of 460 eligible household members of study participants (from all three groups) participated at study endpoint (visit of reinfection or 2-year final visit). Spouses or partners

Table 3. Univariate risk factors associated with *H. pylori* reinfection in Alaskans enrolled in 2-year follow-up after successful treatment for *H. pylori*

Risk factor	Level	Reinfection rate	RR (95% CI)	P value
Age at start of follow-up	≥ 50 years	18%	1.4 (0.7–2.6)	0.37
	<50 years	13%	Ref.	
Sex	Female	17%	1.1 (0.6–2.2)	0.71
	Male	14%	Ref.	
Study arm	Urban NN	12%	0.8 (0.3–2.0)	0.27
	Rural AN	22%	1.6 (0.8–3.3)	
	Urban AN	15%	Ref.	
Crowded house ≥ 1 persons/room	Yes	24%	2.3 (1.2–4.4)	0.01
	No	12%	Ref.	
Child aged <5 years in household	Yes	15%	0.9 (0.4–2.1)	0.8
	No	16%	Ref.	
Currently employed	Yes	12%	0.6 (0.3–1.1)	0.08
	No	20%	Ref.	
Graduated high school	Yes	12%	0.4 (0.2–0.8)	0.003
	No	31%	Ref.	
Drink ETOH	Yes	13%	0.8 (0.4–1.70)	0.46
	No	17%	Ref.	
Smoke >10 cigarettes/day	Yes	19%	1.4 (0.6–3.0)	0.41
	No	15%	Ref.	
Chew tobacco	Yes	28%	1.8 (0.8–4.3)	0.07
	No	15%	Ref.	
Private well water	Yes	13%	0.8 (0.3–1.7)	0.52
	No	16%	Ref.	
Consume lake, spring, river water	Yes	25%	2.0 (1.0–3.9)	0.047
	No	13%	Ref.	
Travel within Alaska	Yes	14%	0.7 (0.3–1.3)	0.24
	No	20%	Ref.	
Own a pet	Yes	19%	1.5 (0.8–3.0)	0.23
	No	12%	Ref.	
Ulcer*	Yes	29%	2.4 (1.2–4.8)	0.01
	No	12%	Ref.	
Previous <i>H. pylori</i> treatment†	Yes	23%	1.8 (0.8–4.0)	0.14
	No	14%	Ref.	
Moderate/severe gastritis‡	Yes	13%	0.6 (0.3–1.3)	0.23
	No	19%	Ref.	
Pre-chew food§	Yes	26%	1.6 (0.6–4.3)	0.31

RR, Risk ratio; CI, confidence interval; AN, Alaska Native; NN, Alaska non-Native.

* History of gastric or duodenal ulcer or ulcer diagnosed at enrolment.

† Previously treated for *H. pylori* in the 10 years prior to enrolment.

‡ At enrolment visit.

§ 'Do you pre-chew food for someone else?'

comprised 25% ($n=81$) of these household members; children and grandchildren accounted for 67% ($n=217$). Overall, 182 (56%) household members were positive for *H. pylori* by ^{13}C -UBT test. The percentage of household members that were *H. pylori*-positive differed by group: group 1 (urban AI/AN) 46% (48/105), group 2 (rural AI/AN) 78% (119/153) and group 3 (urban NN) 23% (15/66), $P<0.0001$. Among all three groups participating in the study, 59 household members of these participants were

tested from households where the study participant was reinfected and 265 members from households where the study participant was not reinfected. After controlling for study arm, household member positivity was associated with *H. pylori* reinfection ($P=0.04$). The reinfection rate was 7.0% in study participants with no household members positive for *H. pylori*, 9.3% when some household members were positive and 27.3% in study participants where every household member tested positive for *H. pylori*. This




Fig. 2. *H. pylori* positivity of household members of study participants by group, Alaska.

association was primarily accounted for by the results within group 2 ($P=0.04$ within this group) vs. group 1 ($P=0.51$ within this group) and group 3 ($P=0.69$ within this group) (Fig. 2).

H. pylori reinfection and water service

In a retrospective oral questionnaire, participants in the rural arm were asked about their access to running water in their homes. Because all participants in urban Anchorage had access to running water, this sub-analysis was restricted to the rural Alaska arm. Only 58/69 participants were available to participate, and 76% (44/58) of them had access to running water in their home. Among persons without running water in their home, 43% were reinfected with *H. pylori* compared to 20% in persons with access to running water (RR 2.3, 95% CI 0.8–6.6).

DISCUSSION

This is the first study examining the rate of *H. pylori* reinfection in AN and NN populations in Alaska. We found a high overall cumulative reinfection rate (16.1%) and elevated rates in all three groups during the first 2 years of follow-up after successful treatment of *H. pylori* compared to other studies in the USA and Europe. The highest cumulative 2-year rate of reinfection (22%) was found in AN persons residing in rural settings (group 2). In one region, where 20% of villages lack running water and flush toilets, 29.9% of participants were reinfected at 2 years. Risk factors for reinfection in study participants were: peptic ulcer disease (past or present), low education level, and having *H. pylori*-positive household members.

The proportion of persons successfully treated for *H. pylori* infection that later become reinfected varies widely throughout the world and, in general, parallels the prevalence of endemicity of this organism in the general population. In developed countries, the risk of reinfection is low, ranging from <1% to 6% [11–14, 21, 22], although reinfection rates as high as 73% have been reported [7–9, 23–27]. The rates of reinfection found in this study are unusually high compared to the rest of the USA and are similar to those found in developing countries. Health disparities exist in rural Alaska which are rarely seen in other parts of the USA, such as lack of access to piped water in the home, lack of flush toilets, and crowded living conditions [28].

Distinguishing between reinfection and recrudescence can be a challenge in *H. pylori* infection; if antimicrobial therapy merely suppresses the organism rather than eradicating it, *H. pylori* could still be present early in the post-treatment period (within the first 2 or 4 months) which could represent recrudescence [29, 30]. In order to account for recrudescence vs. reinfection, we did a separate analysis eliminating the 4-month follow-up results from the calculation for reinfection and determined that overall 11% were reinfected at 2 years. Follow-up OGD examinations could possibly help distinguish between the two by sequencing both the original isolate and the isolate which they later became infected with to determine if sequences were similar, suggesting recrudescence, or dissimilar, suggesting reinfection. However, persons can become reinfected with the same sequence-type isolate, for example from infected household members, and therefore seeing similar sequence types does not necessarily mean recrudescence has occurred.

In addition, OGD is an invasive test and serial OGDs would have been difficult to justify.

We found that the presence of *H. pylori* by ^{13}C -UBT in household members was associated with reinfection at 2 years; the strength of this association was greatest in group 2, AN participants living in rural Alaska. Other factors associated with reinfection included a history of peptic ulcer disease and lower education level (not graduating from high school). Very few studies have reported risk factors associated with reinfection of *H. pylori* after eradication; a recent study by Candelli *et al.* in Italy demonstrated an association between reinfection at 3 years and age and low family income in persons with type 1 diabetes [31] and a study performed by Kim *et al.* in Korea showed an association between reinfection and male gender and low family income [32]. However, to date, few studies have demonstrated an association between reinfection in the index cases and *H. pylori* status in spouses, children or parents nor have they shown any association with household crowding. A recent multi-centre study in South America by Morgan *et al.* demonstrated that *H. pylori* recurrence 1 year post-eradication was associated with an increasing number of children in the household [27]. The general lack of association seen in previous studies could be due to the small sample sizes in these reports.

We were unable to find any studies demonstrating the presence of peptic ulcer or low education level as risk factors for reinfection after eradication of *H. pylori* infection. However, this may be due to the fact that education level and peptic ulcer are rarely looked for as risk factors [15, 26, 33]. In our study, we did not collect information on income level, but lower education level may be a marker for lower socioeconomic status, a documented risk factor for reinfection [15, 32]. Our finding of peptic ulcer as a risk factor for reinfection is important because if *H. pylori* is not eradicated or recurs in a person with a history of peptic ulcer disease, the risk of peptic ulcer recurrence is >50% [7, 34]. By contrast, a long-term follow-up study in Spain of 1000 patients with bleeding ulcers due to *H. pylori* (who were cured) found that only one person during the subsequent 12 months had a bleeding ulcer due to *H. pylori* infection, suggesting that acid suppression therapy could be stopped after successful treatment. [35]

During our study, information from a state-wide database on domestic water service in Alaskan communities became available and we determined that, among all participants in the rural arm of the study

(group 2), 59% (41/69) lived in villages where >90% of homes had access to running water. Of the 41 participants living in villages with in-home water service, 12% (5/41) were reinfected with *H. pylori* compared to 35% (10/28) for persons living in villages where <90% of homes were serviced with water ($P=0.02$, relative rate=2.9). Homes without piped water service must haul treated water from a central watering point in the village and frequently use raw water sources from rivers, lakes or rooftops as a matter of convenience. Due to these findings, we developed a retrospective oral questionnaire asking group 2 study participants about access to running water in their homes. We found a trend towards a higher proportion of persons reinfected in homes without access to running water compared to persons in homes with running water that was not statistically significant; ~20% of communities in rural Alaska do not have running water available to their residents. *H. pylori* has been isolated from drinking water sources [36] and studies from Peru have found that different drinking water sources were associated with *H. pylori* infection in children [37, 38]. More work investigating whether drinking water can be a source of *H. pylori* infection is warranted.

This study has a number of limitations. First, it is not a population-based study; we enrolled persons with gastrointestinal symptoms who were scheduled for OGD and therefore these results are most relevant to persons seeking care for gastrointestinal symptoms and may not be generalizable to the entire population. Second, risk factors for reinfection with *H. pylori* may differ by group; however, this study was not adequately powered to look at these differences within groups 1, 2 and 3. Third, we acknowledge that the 4-month cut point for distinguishing reinfection vs. recrudescence may not adequately distinguish between the two. Fourth, although patients were re-tested for *H. pylori* after having been off PPIs and H2 blockers for ≥ 3 days, when we removed patients who had any PPI use within 30 days of any follow-up visit with a ^{13}C -UBT test, our cumulative 2-year reinfection rate was 17.6% (95% CI 11.7–25.9). Similarly, when we removed patients with any H2 blocker use within 30 days of any follow-up visit with a ^{13}C -UBT test, the cumulative 2-year reinfection rate was 18.0% (95% CI 12.1–26.3); these reinfection rates are similar to the overall 2 year reinfection rate of 16%.

Another important finding of our study is that the presence of symptoms of gastric distress had no bearing on whether a person was reinfected or not

after eradication. Thus, relying on symptoms to judge the success of treatment is unreliable and a 'test of cure' is necessary such as ^{13}C -UBT or stool antigen. The timing of the test-of-cure is important and consideration should be given to performing it later than 4–6 weeks post-treatment, since negative tests performed ≤ 4 months after this date may not rule out recrudescence. This needs further study.

In conclusion, we found high rates of reinfection in three different groups in Alaska, similar to rates found in developing countries where *H. pylori* infection is endemic. This study highlights the importance of demonstrating that *H. pylori* infection is truly eradicated in persons who were born or live in endemic regions of the world, such as rural Alaska. Finally, studies employing longer periods of follow-up with careful examination of potential risk factors need to be performed to better define the long-term risk of reinfection after successful eradication of *H. pylori* infection after antimicrobial treatment.

ACKNOWLEDGEMENTS

The authors thank the follow physicians who contributed patients to this study: Steven Westby MD, Mia Lee MD, John Harvey MD, David Barrett MD, Elaine Callahan MD, Kevin Stange MD, Mark Thorndike MD, Mary Christian MD, Frances Wilson MD, David Powers MD, Richard McGrath MD, Patrick Martinez MD, Bill Eggiman MD, Joe Klejka MD, Michael Swenson MD, Richard Buchanan MD, Charles Shannon MD, Thomas Shreves MD, and James Stragland MD. We also thank the following nurses who helped recruit and follow patients: Helen Peters, Cindy Hamlin, Marilyn Getty, and Susan Seidel. We especially thank Kenneth Petersen MD who was involved with the design of this study.

This study was funded by the Centers for Disease Control and Prevention, a North American Research Centers for Health (NARCH) grant no.: 1 U26 94 00005, and a grant from the Alaska Science and Technology Foundation.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

In this study, antibiotic regimen for treatment was selected by the patient's provider. Providers for group 3 participants were offered free prev-pac kits for their use from TAP Pharmaceuticals. No funding was provided by TAP Pharmaceuticals and TAP

Pharmaceuticals had no access to the data and did not review this manuscript prior to publication.

DECLARATION OF INTEREST

None.

REFERENCES

1. **Kusters JG, van Vliet AH, Kuipers EJ.** Pathogenesis of Helicobacter pylori infection. *Clinical Microbiology Reviews* 2006; **19**: 449–490.
2. **Mandeville KL, et al.** Gastroenterology in developing countries: issues and advances. *World Journal of Gastroenterology* 2009; **15**: 2839–2854.
3. **Bruce MG, Maarros HI.** Epidemiology of Helicobacter pylori infection. *Helicobacter* 2008; **13** (Suppl. 1): 1–6.
4. **Graham DY, et al.** Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. *Gastroenterology* 1991; **100**: 1495–1501.
5. **Luther J, et al.** Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. *American Journal of Gastroenterology* 2010; **105**: 65–73.
6. **Aydin A, et al.** Low reinfection rate of Helicobacter pylori infection in Turkey. *Journal of Clinical Gastroenterology* 2000; **30**: 337–337.
7. **Louw JA, et al.** Helicobacter-pylori eradication in the African setting, with special reference to reinfection and duodenal-ulcer recurrence. *Gut* 1995; **36**: 544–547.
8. **Hoffenberg P, et al.** Comparison of 2 treatment modalities to eradicate Helicobacter pylori. *Revista Medica de Chile* 1995; **123**: 185–191.
9. **RamirezRamos A, et al.** Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. *Clinical Infectious Diseases* 1997; **25**: 1027–1031.
10. **AbuMahfouz MZ, et al.** Helicobacter pylori recurrence after successful eradication: 5-year follow-up in the United States. *American Journal of Gastroenterology* 1997; **92**: 2025–2028.
11. **Adachi M, et al.** Reinfection rate following effective therapy against Helicobacter pylori infection in Japan. *Journal of Gastroenterology and Hepatology* 2002; **17**: 27–31.
12. **Bardhan KD, et al.** Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. *Alimentary Pharmacology & Therapeutics* 2000; **14**: 59–67.
13. **Berstad A, et al.** Follow-up on 242 patients with peptic ulcer disease one year after eradication of Helicobacter pylori infection. *Hepato-Gastroenterology* 1995; **42**: 655–659.
14. **Knippig C, et al.** Prevalence of H. pylori infection in family members of H. pylori positive patients and its influence on the reinfection rate after successful

- eradication therapy: a two-years follow-up. *Zeitschrift Fur Gastroenterologie* 2002; **40**: 383–387.
15. **Rowland M, et al.** Low rates of *Helicobacter pylori* reinfection in children. *Gastroenterology* 1999; **117**: 336–341.
 16. **Parkinson AJ, et al.** High prevalence of *Helicobacter pylori* in the Alaska native population and association with low serum ferritin levels in young adults. *Clinical and Diagnostic Laboratory Immunology* 2000; **7**: 885–888.
 17. **Zhu J, et al.** Prevalence and persistence of antibodies to herpes viruses, *Chlamydia pneumoniae* and *Helicobacter pylori* in Alaskan Eskimos: the GOCADAN Study. *Clinical Microbiology and Infection* 2006; **12**: 118–122.
 18. **McMahon BJ, et al.** Reinfection after successful eradication of *Helicobacter pylori*: a 2-year prospective study in Alaska Natives. *Alimentary Pharmacology & Therapeutics* 2006; **23**: 1215–1223.
 19. **McMahon BJ, et al.** The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for *Helicobacter pylori* infections. *Annals of Internal Medicine* 2003; **139**: 463–469.
 20. **CH BzG.** Purposeful selection of variables in logistic regression. *Source Code for Biology and Medicine* 2008; **3**: 1–8.
 21. **Borody TJ, et al.** *Helicobacter pylori* reinfection rate, in patients with cured duodenal ulcer. *American Journal of Gastroenterology* 1994; **89**: 529–532.
 22. **Cutler AF, Prasad VM.** Long-term follow-up of *Helicobacter pylori* serology after successful eradication. *American Journal of Gastroenterology* 1996; **91**: 85–88.
 23. **Hildebrand P, et al.** Recrudescence and reinfection with *Helicobacter pylori* after eradication therapy in Bangladeshi adults. *Gastroenterology* 2001; **121**: 792–798.
 24. **Leal-Herrera Y, et al.** High rates of recurrence and of transient reinfections of *Helicobacter pylori* in a population with high prevalence of infection. *American Journal of Gastroenterology* 2003; **98**: 2395–2402.
 25. **Soto G, et al.** *Helicobacter pylori* reinfection is common in Peruvian adults after antibiotic eradication therapy. *Journal of Infectious Diseases* 2003; **188**: 1263–1275.
 26. **Rollan A, et al.** The long-term reinfection rate and the course of duodenal ulcer disease after eradication of *Helicobacter pylori* in a developing country. *American Journal of Gastroenterology* 2000; **95**: 50–56.
 27. **Morgan D, et al.** Risk of recurrent *Helicobacter pylori* infection 1 year after initial eradication therapy in 7 Latin American communities. *Journal of the American Medical Association* 2013; **309**: 578–586.
 28. **Hennessy T, et al.** The relationship between in-home water service and the risk of respiratory tract, skin, and gastrointestinal tract infections among rural Alaska natives. *American Journal of Public Health* 2008; **98**: 2072–2078.
 29. **Niv Y.** *H pylori* recurrence after successful eradication. *World Journal of Gastroenterology* 2008; **14**: 1477–1478.
 30. **Xia HX, et al.** Recurrence of *Helicobacter pylori* infection after successful eradication: nature and possible causes. *Digestive Diseases and Sciences* 1997; **42**: 1821–1834.
 31. **Candelli M, et al.** High reinfection rate of *Helicobacter pylori* in young type 1 diabetic patients: a three-year follow-up study. *European Review for Medical and Pharmacological Sciences* 2012; **16**: 1468–1472.
 32. **Kim M, et al.** Long-term follow-up *Helicobacter pylori* reinfection rate and its associated factors in Korea. *Helicobacter* 2013; **18**: 135–142.
 33. **Gisbert JP, et al.** Role of partner's infection in reinfection after *Helicobacter pylori* eradication. *European Journal of Gastroenterology & Hepatology* 2002; **14**: 865–871.
 34. **Borody TJ, et al.** *Helicobacter pylori* reinfection rate, in patients with cured duodenal-ulcer. *American Journal of Gastroenterology* 1994; **89**: 529–532.
 35. **Gisbert JP, et al.** Long-term follow-up of 1,000 patients cured of *Helicobacter pylori* infection following an episode of peptic ulcer bleeding. *American Journal of Gastroenterology* 2012; **107**: 1197–1204.
 36. **Moreno Y, Ferrús MA.** Specific detection of cultivable *Helicobacter pylori* cells from wastewater treatment plants. *Helicobacter* 2012; **17**: 327–332.
 37. **Klein PD, et al.** Water source as risk factor for *Helicobacter pylori* infection in Peruvian children. *Lancet* 1991; **337**: 1503–1506.
 38. **Hulten K, et al.** *Helicobacter pylori* in the drinking water in Peru. *Gastroenterology* 1996; **110**: 1031–1035.